Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK1820 vs Voriconazole in Deep Mycosis
NCT03471988Phase 3Completed
- Sponsor
- Asahi Kasei Corporation
- Start
- Apr 2018
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of isavuconazole in invasive aspergillosis (IA), chronic pulmonary aspergillosis (CPA), mucormycosis and 1 more (2 arms), sponsored by Asahi Kasei Corporation. Primary endpoint: Percentage of patients with adverse events at Day 112. Started Apr 2018; status: completed.
02
Drugs
isavuconazole
03
Conditions
invasive aspergillosis (IA)chronic pulmonary aspergillosis (CPA)mucormycosiscryptococcosis
Beyond the preview
Go deeper on NCT03471988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03471988.